Soligenix Provides Important Highlights and Upcoming Catalysts in Corporate Update Letter
News provided by
Share this article
Share this article
PRINCETON, N.J., Feb. 24, 2021 /PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber. The content of this letter is provided below.
Dear Friends and Shareholders,
I would like to start by thanking you for your continued support, and hope that you and your families are all healthy and well. As 2020 recedes in the rearview mirror, we seem to be turning a corner on the challenges the COVID-19 pandemic has imposed on our everyday lives with promising coronavirus vaccines and a hope to return to a more normal existence in the not too distant future. Hope and rec
CEPI partner INOVIO launches Lassa vaccine Phase I trial in West Africa
ghanavisions.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ghanavisions.com Daily Mail and Mail on Sunday newspapers.
THE EBOLA PREVENTIVE MEASURES
thisdaylive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thisdaylive.com Daily Mail and Mail on Sunday newspapers.